Northwestern University Human Resources

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1851-01-28

Employees: 5K

Market Cap: -

Website: https://www.venturecat.northwestern.edu

Clinical Trials

Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Dietary Supplement: Calcitriol
Drug: Temozolomide

First Posted Date: 2006-03-10

Last Posted Date: 2019-06-04

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT00301067

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Drug: bortezomib
Drug: gemcitabine hydrochloride

First Posted Date: 2006-02-13

Last Posted Date: 2019-05-28

Lead Sponsor: Northwestern University

Target Recruit Count: 32

Registration Number: NCT00290706

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

Not Applicable

Completed

Conditions: Schizophrenia
Schizoaffective Disorder
Bipolar Disorder

Interventions: Drug: aripiprazole vs. ziprasidone
Drug: ziprasidone vs. aripiprazole

First Posted Date: 2006-02-07

Last Posted Date: 2019-08-06

Lead Sponsor: Northwestern University

Target Recruit Count: 49

Registration Number: NCT00288366

Locations: 🇺🇸
Psychiatric Hospital at Vanderbilt, Nashville, Tennessee, United States

Bevacizumab in Treating Patients With Angiosarcoma

Phase 2

Completed

Conditions: Sarcoma

Interventions: Biological: Bevacizumab

First Posted Date: 2006-02-07

Last Posted Date: 2018-06-25

Lead Sponsor: Northwestern University

Target Recruit Count: 32

Registration Number: NCT00288015

Locations: 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States

and more 2 locations

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

Phase 3

Terminated

Conditions: Schizophrenia
Schizoaffective Disorder
Bipolar Disorder

Interventions: Drug: aripiprazole (Abilify)
Drug: ziprasidone (Geodon)

First Posted Date: 2006-02-07

Last Posted Date: 2017-05-25

Lead Sponsor: Northwestern University

Target Recruit Count: 250

Registration Number: NCT00288353

Locations: 🇺🇸
Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States

Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

Phase 1

Terminated

Conditions: Sarcoidosis

Interventions: Biological: Autologous hematopoietic stem cell transplantation
Biological: Allogeneic stem cell transplantation

First Posted Date: 2006-01-26

Last Posted Date: 2018-08-31

Lead Sponsor: Northwestern University

Target Recruit Count: 2

Registration Number: NCT00282438

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Phase 1

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Biological: Hematopoietic Stem Cell Transplantation
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Campath 1H
Drug: GCSF
Drug: Cyclosporins
Drug: Mycophenolate Mofetil

First Posted Date: 2006-01-26

Last Posted Date: 2018-07-30

Lead Sponsor: Northwestern University

Target Recruit Count: 4

Registration Number: NCT00282412

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

First Posted Date: 2006-01-25

Last Posted Date: 2011-08-26

Lead Sponsor: Northwestern University

Target Recruit Count: 19

Registration Number: NCT00281996

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

Completed

Conditions: Obesity

First Posted Date: 2006-01-23

Last Posted Date: 2011-12-20

Lead Sponsor: Northwestern University

Target Recruit Count: 43

Registration Number: NCT00280527

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Early Phase 1

Completed

Conditions: Kidney Cancer

Interventions: Biological: aldesleukin
Biological: denileukin diftitox

First Posted Date: 2006-01-18

Last Posted Date: 2013-05-22

Lead Sponsor: Northwestern University

Target Recruit Count: 20

Registration Number: NCT00278369

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy